Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
279
Completed, industry sponsors, Ophthalmology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed279
279 trials
Showing 1 to 25, recently updated first.
AiViva BioPharma, Inc.Industry
NCT05698329 · 19 participants · Start Mar 2, 2023 · Primary completion Mar 3, 2025
Drug: AIV007 · For: Neovascular Age-related Macular Degeneration; Diabetic Macular Edema; Macular Edema
Sites: Beverly Hills, California; Santa Ana, California; Eugene, Oregon · 6 sites in all
EyeBiotech Ltd.Industry
NCT05919693 · 33 participants · Start Jun 12, 2023 · Primary completion Aug 26, 2024
Drug: Remigromig · For: Neovascular Age-related Macular Degeneration (NVAMD); Diabetic Macular Edema (DME)
Sites: Phoenix, Arizona; Bakersfield, California; Modesto, California · 32 sites in all
BioNanoSim Ltd.Industry
NCT07869953 · 18 participants · Start Mar 7, 2024 · Primary completion Mar 25, 2025
Drug: Oftac: 0.05% tacrolimus ophthalmic emulsion · For: Non-Infectious Anterior Uveitis
Sites: Beersheba, Israel; Haifa, Israel; Jerusalem, Israel · 7 sites in all
- A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular DegenerationCompleted
Bio-Thera SolutionsIndustry
NCT04151212 · 24 participants · Start Oct 30, 2018 · Primary completion Feb 28, 2021
Drug: BAT5906 injection · For: Age-related Macular Degeneration
Sites: Beijing, China
Invirsa, Inc.Industry
NCT05586152 · 84 participants · Start Aug 30, 2022 · Primary completion May 2, 2023
Drug: INV-102; Vehicle · For: Dry Eye Disease
Sites: Rush, New York
- Study of Zifibancimig in Participants With Neovascular Age-related Macular DegenerationPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04567303 · 177 participants · Start Oct 28, 2020 · Primary completion Aug 25, 2026
Drug: Zifibancimig; Ranibizumab · For: Macular Degeneration
Sites: Mesa, Arizona; Phoenix, Arizona; Encino, California · 37 sites in all
EyeBiotech Ltd.Industry
NCT06664502 · 38 participants · Start Nov 12, 2024 · Primary completion Mar 25, 2026
Drug: EYE201 · For: Diabetic Macular Edema (DME); Neovascular Age-related Macular Degeneration (NVAMD); BRVO - Branch Retinal Vein Occlusion
Sites: Scottsdale, Arizona; Modesto, California; Mountain View, California · 27 sites in all
Inflammasome TherapeuticsIndustry
NCT06164587 · 30 participants · Start Apr 18, 2024 · Primary completion May 15, 2026
Drug: K8 · For: Geographic Atrophy; Age-Related Macular Degeneration
Sites: Loma Linda, California; Lexington, Kentucky; Portland, Maine · 9 sites in all
Bio-Thera SolutionsIndustry
NCT04772105 · 60 participants · Start Oct 16, 2020 · Primary completion Nov 6, 2023
Drug: 2.5mg of BAT5906; 4.0mg of BAT5906 · For: Diabetic Macular Edema
Sites: Beijiang, China; Beijing, China; Bengbu, China · 19 sites in all
- A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular DegenerationCompleted
EyevensysIndustry
NCT07024732 · 8 participants · Start Jun 23, 2025 · Primary completion Apr 7, 2026
Drug: PST-611 · For: Dry Age Related Macular Degeneration
Sites: Grenoble, France; Paris, France
Nacuity Pharmaceuticals, Inc.Industry
NCT04355689 · 49 participants · Start Sep 3, 2020 · Primary completion Jun 20, 2025
Drug: NPI-001 · For: Usher Syndromes
Sites: Brisbane, Australia; Melbourne, Australia; Perth, Australia · 4 sites in all
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular EdemaPivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT06850922 · 388 participants · Start Jun 22, 2022 · Primary completion May 19, 2026
Drug: RO7446603; Aflibercept and 1 more · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Springdale, Arkansas; Campbell, California · 77 sites in all
Visara, Inc.Industry
NCT05940428 · 10 participants · Start Oct 23, 2023 · Primary completion Oct 21, 2024
Drug: ASKG712 · For: Diabetic Macular Edema
Sites: Beijing, China
Cambium Bio LimitedIndustry
NCT03414645 · 64 participants · Start May 1, 2018 · Primary completion Dec 12, 2019
Drug: CAM-101 10%; Vehicle Control and 1 more · For: Dry Eye; Graft-versus-host-disease; Ocular Discomfort
Sites: Palo Alto, California; Boston, Massachusetts; Ann Arbor, Michigan · 6 sites in all
Visara, Inc.Industry
NCT05456828 · 56 participants · Start Feb 10, 2023 · Primary completion Nov 3, 2025
Drug: ASKG712 · For: Neovascular Age-related Macular Degeneration
Sites: Shanghai, China
RudacureIndustry
NCT07640867 · 40 participants · Start Oct 28, 2024 · Primary completion Aug 29, 2025
Drug: RCI001 Eye Drops 0.25%; Placebo Eye Drops · For: Dry Eye
Sites: Seoul, South Korea
- A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis PigmentosaCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03374657 · 12 participants · Start Aug 22, 2018 · Primary completion May 12, 2026
Drug: CPK850 · For: Retinitis Pigmentosa
Sites: Stockholm, Sweden
Perfuse Therapeutics, Inc.Industry
NCT05822245 · 33 participants · Start May 25, 2023 · Primary completion Apr 20, 2025
Drug: PER-001 Intravitreal Implant - Low Dose; PER-001 Intravitreal Implant - High Dose and 1 more · For: Open-angle Glaucoma
Sites: San Francisco, California
PYC TherapeuticsIndustry
NCT06455826 · 6 participants · Start Jun 13, 2024 · Primary completion Sep 24, 2025
Drug: VP-001 · For: Retinitis Pigmentosa 11; Retinal Degeneration; Eye Diseases and 2 more
Sites: Jacksonville, Florida; Ann Arbor, Michigan; Portland, Oregon · 5 sites in all
NexThera Co., Ltd.Industry
NCT06704009 · 20 participants · Start Mar 11, 2025 · Primary completion Dec 15, 2025
Drug: NT-101 Low Dose; NT-101 High Dose · For: Wet Age Related Macular Degeneration; Wet AMD
Sites: Rosedale, Maryland; Durham, North Carolina; Erie, Pennsylvania · 4 sites in all
Kiora Pharmaceuticals, Inc.Industry
NCT05282953 · 32 participants · Start Nov 10, 2022 · Primary completion Aug 10, 2023
Drug: KIO-301 · For: Retinitis Pigmentosa; Choroideremia; Non-Syndromic Rod-Dominant Inherited Retinal Diseases
Sites: Sydney, Australia; Adelaide, Australia; North Adelaide, Australia
Exegenesis BioIndustry
NCT05903794 · 12 participants · Start Jul 24, 2023 · Primary completion Feb 16, 2026
Drug: EXG102-031 · For: Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Sites: Reno, Nevada; Erie, Pennsylvania
- A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324Pivotal-lookingCompleted
Ollin Biosciences, Inc.Industry
NCT07484074 · 164 participants · Start Feb 12, 2025 · Primary completion Oct 10, 2025
Drug: Faricimab; OLN324 · For: Diabetic Macular Edema (DME); Neovascular (Wet) Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Glendale, California; Pasadena, California · 30 sites in all
- IVW-1001 Phase 1/2 in Subjects With Dry Eye DiseasePivotal-lookingCompleted
IVIEW Therapeutics Inc.Industry
NCT06400459 · 150 participants · Start Jun 25, 2024 · Primary completion Oct 15, 2024
Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.1%; IVW-1001 Ophthalmic Eyelid Wipe 0.2% and 1 more · For: Dry Eye Disease
Sites: Houston, Texas
AbbVieAbbVie (ABBV)
NCT02556736 · 14 participants · Start Dec 14, 2015 · Primary completion Jun 1, 2020
Drug: AGN-151597 · For: Advanced Retinitis Pigmentosa
Sites: San Francisco, California; Edgewood, Kentucky; Durham, North Carolina · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.